393-85-1

Usage

Uses

Used in Organic Synthesis:
2-Nitro-5-fluorobenzoic Acid, Methyl Ester is used as an intermediate in organic synthesis for the production of various pharmaceuticals, agrochemicals, and other specialty chemicals. Its presence of both electron-withdrawing nitro and fluoro groups, along with the reactivity of the methyl ester, makes it a versatile building block for the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-Nitro-5-fluorobenzoic Acid, Methyl Ester is utilized as a key component in the development of new drugs. Its unique structure allows for the creation of novel compounds with potential therapeutic properties, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
2-Nitro-5-fluorobenzoic Acid, Methyl Ester is also employed in the agrochemical sector for the synthesis of active ingredients in pesticides and herbicides. Its ability to form stable derivatives with biological activity makes it a valuable precursor in the development of effective crop protection agents.

InChI:InChI=1S/C8H6FNO4/c1-14-8(11)6-4-5(9)2-3-7(6)10(12)13/h2-4H,1H3

Upstream product

• 67-56-1 methanol 
• 394-02-5 5-fluoro-2-nitrobenzoyl chloride 
• 320-98-9 5-fluoro-2-nitrobenzoic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 74-89-5 methylamine 
• 77-78-1 dimethyl sulfate 
• 455-68-5 methyl 3-fluorobenzoate 

Downstream Products

• 221540-42-7 diethyl 3-methoxycarbonyl-4-nitrophenylmalonate 
• 946604-95-1 5-butoxy-2-nitrobenzoic acid methyl ester 
• 886978-05-8 methyl 5-[4-(ethylsulfonyl)phenoxy]-2-nitrobenzoate 
• 1192319-05-3 methyl 5-(3-aminophenoxy)-2-nitro-benzoate 
• 1192319-26-8 5-(3-tert-butoxycarbonylaminophenoxy)-2-nitrobenzoic acid methyl ester 
• 1192319-06-4 methyl 5-(4-(methylamino)phenoxy)-2-nitrobenzoate 
• 1192318-91-4 methyl 2-acetamido-5-(3-(methoxycarbonyl)-4-nitrophenoxy)-benzoate 
• 1192318-88-9 methyl 5-(2,2-dimethyl-4-oxo-4H-benzo[d][3,1]dioxin-6-yloxy)-2-nitrobenzoate 
• 1192319-12-2 methyl 5-(4-(4-fluorophenylamino)phenoxy)-2-nitrobenzoate 
• 951668-06-7 methyl 5-[4-nitro-3-(methoxycarbonyl)-phenoxy]-2-[(4-methylphenyl)sulfonyl]aminobenzoate 
• 1350456-27-7 methyl 3-(2-hydroxyethylthio)-6-nitrobenzoate 
• 1423007-83-3 methyl 5-{N-[5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)-1-benzofuran-6-yl]methanesulfonamido}-2-nitrobenzoate 
• 773851-04-0 5-fluoro-1H-benzo[c]isoxazol-3-one 
• 749863-29-4 methyl 5-(dimethylamino)-2-nitrobenzoate 

Relevant academic research and scientific papers

Discovery of 5-(4-methylpiperazin-1-yl)-2-nitroaniline derivatives as a new class of SIRT6 inhibitors

SIRT6 is a deacetylase of histone H3 and inhibitors of SIRT6 have been thought as potential agents for treatment of diabetes. Herein we report the discovery of a series of new SIRT6 inhibitors containing the skeleton 1-phenylpiperazine. Among them, compound 5-(4-methylpiperazin-1-yl)-2-nitroaniline (6d) is the most potent one, which showed an IC50 value of 4.93 μM against SIRT6 in the Fluor de Lys (FDL) assay. It displayed KD values of 9.76 μM and 10 μM in surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) assays, respectively. In selectivity assay, 6d showed no activity against other members of the HDAC family (SIRT1-3 and HDAC1-11) at concentrations up to 200 μM. In a mouse model of type 2 diabetes, 6d could significantly increase the level of glucose transporter GLUT-1, thereby reducing blood glucose. Overall, this study provides a promising lead compound for subsequent drug discovery targeting SIRT6.

2-METHYL-QUINAZOLINES

The present invention describes 2-methyl-quinazoline compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions. The 2-methyl substituted quinazoline compounds of general formula(I) effectively and selectively inhibit the Ras-Sos interaction without significantly targeting the EGFR receptor. They are therefore useful for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, such as cancer as a sole agent or in combination with other active ingredients.

Synthesis of 2′,3′-dideoxynucleosides for automated DNA synthesis and pyrophosphorolysis activated polymerization

Methods for preparation of 2′,3′-dideoxynucleotides support structures, such as 2′,3′-dideoxyguanosine, 2′,3′-dideoxyadenosine, and 3′-deoxythymidine support structures are disclosed. Various methods of using such structures are also provided, such as their use for automated DNA synthesis and pyrophosphorolysis activated polymerization.

HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM

The present invention concerns a fluorescence resonance energy transfer based high throughput test system to measure the formation of the HIV gp41 six-helix bundle. In a first embodiment the current invention relates to a homogeneous time resolved fluorescence-based test system comprising a first helical polypeptide consisting essentially of the sequence of IQN36 (SEQ ID NO:1); a second helical polypeptide consisting essentially of the sequence of C34 (SEQ ID NO: 2) wherein said IQN36 is labeled with a light emitting fluorophore and said C34 is labeled with an ultra-violet excitable fluorophore.

SUBSTITUTED AMINO-QUINAZOLINONES, MEDICAMENTS COMPRISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE

The present invention relates to substituted amino-quinazolinones of general formula (I) wherein the groups R1 to R14 and A, are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.

BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS

There is provided compounds of formula I, wherein ring A, D1, D2a, D2b, D3, L1, Y1, L3 and Y3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and/or required, and particularly in the treatment of a respiratory disorder and/or inflammation.

ARYLOXY-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES

A glucokinase activator is provided; and a treatment and/or a preventive for diabetes, or a treatment and/or a preventive for diabetes such as retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis, and further a treatment and/or a preventive for obesity are provided. The invention relates to a compound of a formula (I): [wherein R1 and R2 represent a hydrogen, etc.; R3 represents a hydrogen atom, a halogen atom, etc.; R4 each independently represents a hydrogen atom, a lower alkyl group, etc.; Q represents a carbon atom, a nitrogen atom or a sulfur atom (the sulfur atom may be mono- or di-substituted with an oxo group); R5 and R6 each represent a hydrogen atom, a lower alkyl group, etc.; X1, X2, X3 and X4 each independently represent a carbon atom or a nitrogen atom; Z represents an oxygen atom, a sulfur atom or a nitrogen atom; Ar represents an aryl or heteroaryl group optionally mono to tri-substituted with a group selected from the substituent group β; ring A represents a 5- or 6-membered nitrogen-containing heteroaromatic group; m indicates an integer of from 1 to 6; n indicates an integer of from 0 to 3; p indicates an integer of from 0 to 2 (provided that at least two of X1 to X4 are carbon atoms); q indicates 0 or 1] or its pharmaceutically-acceptable salt, which has an effect of glucokinase activation and is useful as a treatment for diabetes.

NOVEL AZACYCLY-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS

The invention relates to azacyclyl-substituted arylthienopyrimidinones and their derivatives of formula (I), and their physiologically tolerated salts and physiologically functional derivatives, their preparation, medicaments comprising at least one azacyclyl-substituted arylthienopyrimidinone of the invention or its derivative, and the use of the azacyclyl-substituted aryithienopyrimidinones of the invention and their derivatives as MCH antagonists.

SUBSTITUTED ISOQUINOLINONES

Isoquinolinone compounds are provided that are useful for the inhibition of ADP-platelet aggregation, particularly in the treatment of thrombosis and thrombosis related conditions or disorders.

P38 inhibitors and methods of use thereof

This invention relates to inhibitors of p38, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders mediated by p38.